Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

Recent & Breaking News (TSXV:BTI)

IIROC Trading Resumption - BTI

Canada NewsWire December 4, 2017

IIROC Trade Resumption - biOasis Technologies Inc.

Newsfile December 4, 2017

IIROC Trade Halt - biOasis Technologies Inc.

Newsfile December 4, 2017

IIROC Trading Halt - BTI

Canada NewsWire December 4, 2017

Bioasis Implements Transition Plan for Its Board of Directors

Business Wire December 4, 2017

Bioasis Establishes U.S. Presence with Office in Connecticut

Business Wire October 10, 2017

biOasis Appoints Christopher P. Lowe, M.B.A. as Chief Financial Officer and Board Advisor

Business Wire October 2, 2017

biOasis Welcomes Dr. Nancy Stagliano, Dr. Deborah Rathjen and Dr. Maha Radhakrishnan to Its Board of Directors

Business Wire September 25, 2017

biOasis Announces Voting Results for 2017 Annual Meeting

Business Wire September 21, 2017

biOasis Announces Rob Hutchison, Founder, to Retire as Chairman & Board Member

Business Wire September 18, 2017

biOasis Announces Formation of Scientific Advisory Board to Advance the Science for the Company’s Blood-Brain Barrier Drug Delivery Platform

Business Wire September 7, 2017

biOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders

Marketwired August 28, 2017

biOasis Appoints Doug Williams, MBA, Executive Vice President, Chief Business Officer

MarketWire Canada August 21, 2017

biOasis Appoints Catherine London, Executive Vice President, Head of Corporate Communications and Investor Relations

MarketWire Canada June 25, 2017

biOasis Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities

MarketWire Canada June 15, 2017

biOasis CEO Dr. Mark Day Releases Details of Corporate Plans in Message to Shareholders

MarketWire Canada June 13, 2017

biOasis to Present at The Global Chinese Financial Forum - Shanghai Conference 2017

MarketWire Canada June 8, 2017

biOasis to Present at the 16th International Postgraduate Course on Lysosomal Storage Disorders

MarketWire Canada June 4, 2017

biOasis Appoints Mark Day, Ph.D., as Chief Executive Officer and Director

MarketWire Canada April 24, 2017

biOasis Closes Oversubscribed Non-Brokered Private Placement

MarketWire Canada April 11, 2017